Curated News
By: NewsRamp Editorial Staff
June 02, 2025
Nutriband Inc. Reports Strong Q1 Revenue Growth and Strategic Partnerships
TLDR
- Nutriband (NASDAQ: NTRB) reported 63% revenue increase, focusing on shareholder value by expanding kinesiology tape production and retail presence.
- Nutriband is developing AVERSA Fentanyl patch with abuse-deterrent technology, emphasizing prevention of drug abuse, misuse, diversion, and accidental exposure.
- Nutriband's AVERSA technology aims to make the world better by preventing drug abuse and promoting safer transdermal drug delivery methods.
- Nutriband partners with Kindeva for AVERSA Fentanyl patch, projected to achieve $80-200 million U.S. sales annually, enhancing drug delivery technology.
Impact - Why it Matters
This news matters because Nutriband's significant revenue growth and strategic partnerships indicate a promising future for the company, especially with the development of AVERSA Fentanyl patch. Investors and stakeholders should take note of the company's expansion plans and innovative product pipeline, which could have a positive impact on its market position and shareholder value.
Summary
Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, Walmart, Walgreens, and CVS. The company continues to prioritize shareholder value by scaling Pocono’s output through penetration pricing strategies while advancing development of AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch. A newly formalized partnership with Kindeva Drug Delivery will support shared development costs in exchange for milestone payments as AVERSA moves toward regulatory approval. The product is projected to reach peak U.S. sales of $80 million to $200 million annually.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Inc. Reports Strong Q1 Revenue Growth and Strategic Partnerships
